We are evaluating competing offers from a private equity firm and a strategic competitor. The strategic is offering a higher multiple, but their terms are loaded with integration milestones and non-competes. How do we weigh the headline valuation multiple against execution risk between these buyer types?
When comparing offers, a strategic buyer will often offer a higher top-line valuation multiple than a private equity financial sponsor because the strategic can model hard cost synergies, customer overlap, and cross-selling scale. However, higher headline multiples often come with significantly higher deal risk and operational disruption.
Strategic buyers conduct invasive diligence. They want deep access to your customer lists, margin profiles, and proprietary processes. If the transaction falls apart during exclusivity, you have handed your competitive playbook directly to an active competitor. Furthermore, strategics frequently insist on lengthy transition periods, onerous non-compete agreements, and earnout structures tied to complex post-merger integration goals that you cannot control once they take ownership.
Financial sponsors, by contrast, focus on cash flow continuity, leadership depth, and scalable systems. They value a self-managing Leadership Team and an established operating system like EOS. They rarely cannibalize your brand, and their diligence focuses on financial predictability and compliance rather than stealing trade secrets.
When deciding between the two:
- Require strict confidentiality protocols with strategics, including redacted customer diligence and clean room agreements where sensitive data is only reviewed by third-party advisors until definitive documents are executed.
- Evaluate net certainty of close. A lower multiple from a credible private equity sponsor with committed capital and no antitrust hurdles is often worth more than an inflated, uncommitted strategic offer loaded with earnout contingencies.
Base your decision on net walk-away certainty, not headline vanity multiples.
Category: Valuation & Deal Structure